InvestorsHub Logo
Followers 6
Posts 108
Boards Moderated 0
Alias Born 08/30/2013

Re: None

Tuesday, 08/12/2014 4:06:53 PM

Tuesday, August 12, 2014 4:06:53 PM

Post# of 32016
Evaluating the Sanofi partnership

From SNY POV, this seems like a winning deal. From MNKD, investors will need to wait on sales projections and traction of Afrezza on diabetic care market.

MannKind's primary concern was getting the best leading diabetic large pharma to market Afrezza. They did that with Sanofi, even if it means sacrificing a little on the terms. Will it be worth it in the end?

http://bit.ly/1r7pwDX
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y